Other languages ORIC Pharmaceuticals, Inc.

Equities

ORIC

US68622P1093

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
9.51 ^USD	-2.56%		-4.90%	+3.37%

Apr. 15	ORIC Pharmaceuticals Doses First Patients in Expansion Groups in Phase 1b Trial of ORIC-114 to Treat Lung Cancer	MT
Apr. 15	ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC	Apr. 15
ORIC Pharmaceuticals, Inc Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research Annual Meeting	Apr. 08
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 11
Oric Pharmaceuticals Insider Sold Shares Worth $648,380, According to a Recent SEC Filing	Mar. 08
Oric Pharmaceuticals Insider Sold Shares Worth $489,346, According to a Recent SEC Filing	Feb. 09
ORIC Pharmaceuticals Launching $125 Million Private Placement	Jan. 22
ORIC Pharmaceuticals, Inc. Provides Initial Phase 1B Data for Oric-944	Jan. 08
ORIC Pharmaceuticals Says Initial Phase 1 Dose Escalation Data for ORIC-533 Shows Evidence of Clinical Antimyeloma Activity	Dec. 11
ORIC Pharmaceuticals, Inc. Announces Initial Data from the Ongoing ORIC-533 Phase 1 Dose Escalation Trial in Patients with Relapsed/Refractory Multiple Myeloma At the 65th American Society of Hematology Annual Meeting	Dec. 11
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06
ORIC Pharmaceuticals, Inc. Announces Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations	23-10-21
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
ORIC Pharmaceuticals Launches $85 Million Private Placement; Shares Extend Gains Premarket	23-06-27
ORIC Pharmaceuticals Launches $85 Million Private Placement; Shares Rise	23-06-26
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08
2022, une année boursière toute pourrie	23-01-02
En Direct des Marchés : Airbus, Atos, Alstom, Alten, Valneva, Chevron, ING, Ferrovial...	23-01-02
Pfizer Discloses 12% Stake in ORIC Pharmaceuticals	22-12-30
Sector Update: Healthcare Stocks Finish Narrowly LowerThursday	22-12-22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages ORIC Pharmaceuticals, Inc.

Equities

ORIC

US68622P1093

Other languages

Filters